Associate-Director Flow and Image Cytometry Roswell Park ComprehensiveCancer Center

罗斯威尔公园综合癌症中心流式和图像细胞术副主任

• 批准号: 10693283
• 负责人: HANS MINDERMAN
• 金额: $ 34.21万
• 依托单位: ROSWELL PARK CANCER INSTITUTE CORP
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-20 至 2027-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10693283
• 关键词: Applications Grants; Area; Award; Biological Assay; Cancer Center; Cancer Center Support Grant; Clinical; Collaborations; Comprehensive Cancer Center; Consult; Consultations; Data Analyses; Dedications; Doctor of Philosophy; Education; Ensure; Equipment; Experimental Designs; Extramural Activities; Faculty; Flow Cytometry; Funding; Funding Opportunities; Grant; Image; Image Cytometry; Infrastructure; Investments; Laboratories; Maintenance; Microscope; Positioning Attribute; Principal Investigator; Reporting; Research; Research Personnel; Research Project Grants; Resource Sharing; Resources; Scientist; Specialist; United States National Institutes of Health; Wages; base; cancer research center director; career; experience; live cell imaging; member; neoplasm immunotherapy; programs; tumor immunology

The current application seeks continued salary support for Hans Minderman, PhD who serves as the Associate Director of the Flow and Image Cytometry Shared Resource (FICSR) of the Roswell Park Comprehensive Cancer Center (Roswell Park). This position was created in 2007 to oversee the research applications of the various imaging (confocal, live cell imaging) and flow cytometry platforms available in the facility and to apply his extensive experience in these areas in collaborations and consultations with the FICSR investigator user base. With over 35 years of experience in clinical and research applications of flow and image cytometry (30 years at Roswell Park), Dr Minderman throughout his career has collaborated with many investigators at the Cancer Center on NIH funded projects. The FICSR is an integral part of Roswell Park’s Cancer Center Support grant (P30CA016056) for which the cancer center Director, Dr Johnson serves as the Principal Investigator. The Tumor Immunology & Immunotherapy (TII) CCSG program, previously co-led by the Unit Director on the original application, Dr Odunsi, is the major user base of the FICSR; but numerous NIH-funded researchers across all 5 CCSG programs actively collaborate and consult with Dr Minderman commensurate with the purpose of the PAR 21-286 funding opportunity. During his first R50 tenure (2016-2021), Dr Minderman’s contributions to Roswell Parks research enterprise have been significant and impactful specifically with regards to the NIH-funded research. As of October 2021, 137 extramural grant applications dependent on FICSR were awarded to Roswell Park faculty, 59 were awarded by NIH, 22 of which to members of the TII program. The cancer center has also made significant investments in the FICSR with the acquisition of a new confocal microscope, two spectral flow cytometry analyzers and a 3rd Fortessa analyzer. With the changes in the R50 program now making the distinction between Laboratory (PAR-20-288)- and Core (PAR-20-287)-based scientists and with the FICSR being an integral part of the Roswell Park CCSG infrastructure, Dr Johnson as the PI of the CCSG grant, will now serve as the Unit Director for the renewal application.

目前的申请为Hans Minderman博士寻求持续的薪水支持

项目成果

Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)

• DOI: 10.1002/eji.201970107
• 发表时间: 2019-10-01
• 期刊: EUROPEAN JOURNAL OF IMMUNOLOGY
• 影响因子: 5.4
• 作者: Cossarizza, Andrea;Chang, Hyun-Dong;Zychlinsky, Arturo
• 通讯作者: Zychlinsky, Arturo